Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
JPMorgan upgraded Bluebird Bio (BLUE) to Neutral from Underweight without a price target after the company entered into a definitive agreement ...
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
Verizon completes its first satellite to cellular enabled video call with AST SpaceMobile BlueBird 2
Verizon and AST have yet again pushed the boundaries of what can be done with mobile devices by successfully trialing a live video call between two mobile devices with one connected via satellite and ...
12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...
Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be ...
Hand crews will work over the next year to form a new fuel modification zone in the Bluebird Canyon area of Laguna Beach, the ...
Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results